N-(2-Aminoethyl)-1-aziridineethanamine is an experimental ACE2 inhibitor for the treatment of cardiovascular disease and Severe Acute Respiratory Syndrome. An experimental medication to treat heart disease and SARS.
- Mechanism
- Curator reviewed · 4 references
Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption. This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation. N-(2-Aminoethyl)-1-aziridineethanamine may inhibit ACE2, preventing these actions from occurring.
N-(2-Aminoethyl)-1-aziridineethanamine binding to ACE2 may lead to a conformational change in ACE2, shifting the residues that would bind SARS-CoV S-glycoprotein, preventing viral attachment and entry.
- Primary indication
- This experimental drug was being researched for its use in the treatment of cardiovascular disease and SARS-CoV infections.Curator reviewed
- Formula / weight
- C6H15N3 · 129.207 g/mol (avg)
- Also known as
- N-(2-((2-Aminoethyl)amino)ethyl)aziridine · N-(2-aminoethyl)-1 aziridine-ethanamine
Resolves to
XJNAQZHMIAKQOK-UHFFFAOYSA-NSMILESNCCNCCN1CC1What you can answer from here — as of April 02, 2025
Which drugs share a target with N-(2-Aminoethyl)-1-aziridineethanamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account